Asset Details
Do you wish to reserve the book?
The effect of tailored consumer medicine information on patients with type 2 diabetes mellitus: A randomised controlled interventional study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The effect of tailored consumer medicine information on patients with type 2 diabetes mellitus: A randomised controlled interventional study
Do you wish to request the book?
The effect of tailored consumer medicine information on patients with type 2 diabetes mellitus: A randomised controlled interventional study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The effect of tailored consumer medicine information on patients with type 2 diabetes mellitus: A randomised controlled interventional study
2020
Overview
Introduction In patients with diabetes, better health communication is associated with better health outcomes including medication adherence and glycaemic control. The conventional patient information leaflet does not consider the cultural and behavioral perspectives of diverse patient populations. Consumer medicine information (CMI) is a written information about the prescription drugs developed by organisations or individuals other than a drug manufacturer that is intended for distribution to consumers at the time of medication dispensing. Objective This study aimed to evaluate the impact of CMI on medication adherence and glycaemic control among patients with type 2 diabetes in Qatar. Methods We developed and customised CMI for all the anti‐diabetic medications used in Qatar. A randomised controlled trial in which the intervention group patients (n = 66) received the customised CMI with usual care, while the control group patients (n = 74) received usual care only, was conducted. Self‐reported medication adherence and haemoglobin A1c (HbA1c) were the primary outcome measures. Glycaemic control and medication adherence parameters were measured at baseline, 3 months, and 6 months in both groups. Medication adherence was measured using the 8‐item Morisky Medication Adherence Scale (MMAS‐8). Results Although the addition of CMI resulted in better glycaemic control, this did not reach statistical significance, possibly because of the short‐term follow‐up. The median MMAS‐8 score improved from baseline (6.6 [IQR = 1.5]) to 6‐month follow‐up (7.0 [IQR = 1.00]) in the intervention group. In addition, there was a statistically significant difference between the intervention and the control groups in terms of MMAS‐8 score at the third visit (7.0 [IQR = 1.0]) vs 6.5 (IQR = 1.25; P‐value = .010). Conclusion CMI for anti‐diabetic medications when added to usual care has the potential to improve medication adherence and glycaemic control among patients with type 2 diabetes. Therefore, providing better health communication and CMI to patients with diabetes is recommended.
Publisher
John Wiley & Sons, Inc
Subject
/ Consumer Health Information - methods
/ Diabetes
/ Diabetes mellitus (non-insulin dependent)
/ Diabetes Mellitus, Type 2 - blood
/ Diabetes Mellitus, Type 2 - drug therapy
/ Female
/ Glycated Hemoglobin A - analysis
/ Humans
/ Information Dissemination - methods
/ Information Seeking Behavior
/ Male
/ Medication Adherence - statistics & numerical data
/ Patient Education as Topic - methods
/ Qatar
